ModifiedmhnPolicy CP.PMN.300

Aripiprazole Orally Disintegrating Tablet, Oral Film (Opipza, Mezofy)

This policy describes medical necessity criteria, dosing limits, and prior authorization requirements for aripiprazole ODT and oral film formulations (Opipza, Mezofy) for commercial, HIM, and Medicaid lines of business. It governs prescribers and pharmacy benefit managers handling requests for these products; Medicaid does not require prior authorization for aripiprazole ODT.

Policy Summary

Payermhn

PolicyAripiprazole Orally Disintegrating Tablet, Oral Film (Opipza, Mezofy)

Policy CodePolicy CP.PMN.300

Change TypeAdded Opipza and Mezofystep therapy added

Effective DateMar 1, 2025

Next Review Date

Key ActionSubmit prior authorization with documentation demonstrating trials of generic aripiprazole tablet and oral solution (and ODT where required) or documentation of contraindication before branded formulations will be authorized.

SourceLink

POLICY UPDATE CHANGES

Added new formulation Opipza to policy with step therapy requirement for generic aripiprazole tablet, oral solution, and ODT per SDC.

Added newly approved Mezofy to policy.

Policy was adapted from previously approved policy CP.PCH.37 (retired) and Medicaid line of business was added.

12 monthstypical approval duration

≥13minimum age (schizophrenia)

30 mg/daymax dose (schizophrenia/bipolar)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Initial Approval

Covered when ALL of the following are met

Initial approval - FDA indications and eligibility: 1) Diagnosis of one of: schizophrenia, bipolar disorder, major depressive disorder (MDD), autistic disorder, or Tourette's disorder; 2) Age meets indication-specific minimums: schizophrenia ≥13 years; bipolar disorder ≥10 years; MDD ≥18 years; autistic disorder age 6–17 years; Tourette's disorder age 6–18 years; 3) For bipolar disorder requests, formulation must be aripiprazole ODT; 4) For Mezofy requests, request must be for schizophrenia; 5) For aripiprazole ODT requests, member must have used generic aripiprazole tablet and oral solution unless clinically significant adverse effects or both are contraindicated; 6) For Opipza requests, member must have used generic aripiprazole tablet, oral solution, and ODT unless clinically significant adverse effects are experienced or all are contraindicated; 7) For MDD (adjunctive therapy), aripiprazole ODT or Opipza must be prescribed concurrently with an antidepressant; 8) Dose does not exceed indication-specific maximums (see dose constraints).

Reflects section I initial approval criteria

inv-02: Dose constraints

Dose limits (must meet the applicable one for the diagnosis)

Dose limits: Schizophrenia: maximum 30 mg/day (product-specific per-day limits: aripiprazole ODT 2 tablets/day; Opipza 3 films/day; Mezofy 2 films/day). Bipolar disorder: maximum 30 mg/day and maximum 2 tablets/day (aripiprazole ODT). MDD or autistic disorder (irritability associated with autistic disorder): maximum 15 mg/day — one of: aripiprazole ODT 1 tablet/day or Opipza 2 films/day. Tourette's disorder: if weight <50 kg — maximum 10 mg/day (aripiprazole ODT 1 tablet/day or Opipza 1 film/day); if weight ≥50 kg — maximum 20 mg/day (aripiprazole ODT 2 tablets/day or Opipza 2 films/day). Specific product tablet/film limits referenced in dosing and quantity limit sections apply (see dosing table).see text

Dose constraints drawn from initial and continuation sections

inv-03: Continuation Therapy

Continuation (renewal) approval requires ALL of the following

Continuation therapy: 1) Member is currently receiving the medication via the benefit, or documentation supports the member has received aripiprazole ODT, Opipza, or Mezofy for a covered indication for at least 30 days; 2) Member is responding positively to therapy; 3) For bipolar disorder, renewal requests must be for aripiprazole ODT; 4) For Mezofy, renewal requests must be for schizophrenia; 5) If the request is for a dose increase, the new dose must not exceed the indication-specific maximums listed under dosing limits.

Continuation criteria from section II

inv-04: Other / Off-label routing

Other diagnoses/indications: 1) If the drug has undergone a label change within the last 6 months not yet reflected in this policy, refer to the applicable formulary/no-coverage or non-formulary policy for the line of business; 2) If the requested use is not listed under section III (non‑authorized indications) and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, CP.PMN.255 for Medicaid).

Administrative routing for recent label changes or off-label uses

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the off‑label use policies: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, or CP.PMN.255 for Medicaid (or appropriate evidence of coverage documents).

No exclusions beyond those noted elsewhere in the policy are explicitly stated in the provided document portion.

Uses for non‑FDA approved indications that are not supported by clinical evidence and are not covered under the referenced off‑label use policies are not authorized for coverage.

Within the supplied document excerpts there are no explicit statements framed as "not medically necessary."

Initial Therapy Requirements

inv-21: Initial Therapy

Initial approval requires meeting indication, age, formulation, prior-use and dosing criteria

Initial therapy nodes: 1) Diagnosis must be an FDA‑approved indication (schizophrenia, bipolar disorder, MDD, autistic disorder, or Tourette's disorder); 2) Age must meet indication-specific minimums (schizophrenia ≥13; bipolar ≥10; MDD ≥18; autistic disorder 6–17; Tourette's 6–18); 3) For bipolar disorder, the requested product must be aripiprazole ODT; 4) Product-specific prior-use requirements: for aripiprazole ODT requests, trial of generic aripiprazole tablet and oral solution is required unless clinically significant adverse effects or contraindications exist; for Opipza and Mezofy requests, required prior trials include generic aripiprazole tablet, oral solution, and ODT unless clinically significant adverse effects or contraindications exist; 5) For MDD (adjunctive use), aripiprazole ODT or Opipza must be used with an antidepressant; 6) Dose must not exceed indication-specific maximums (see dose constraints).

Initial approval criteria (detailed)

inv-22: Initial coverage requirements for Opipza

Step therapy for newly added branded formulations

Opipza coverage prerequisite:

Continuation / Renewal Criteria

inv-23: Continuation

Renewal approval requirements

Continuation therapy nodes: 1) Member has been on the medication for ≥30 days or is currently receiving it via the benefit; 2) Member is responding positively to therapy; 3) Formulation- and indication-specific requirements apply on renewal (bipolar disorder requires ODT; Mezofy limited to schizophrenia); 4) Any requested dose increase must not exceed the indication-specific maximums listed under dosing limits.

Continuation criteria from drug policy continuation section

Step Therapy Requirements

Step	Requirement
1	Trial and use of generic aripiprazole tablet and aripiprazole oral solution is required prior to approval of aripiprazole ODT unless clinically significant adverse effects are experienced or both formulations are contraindicated.

Step	Requirement
1	Trial and failure of, or contraindication to, generic aripiprazole tablet, aripiprazole oral solution, and aripiprazole ODT is required prior to coverage of Opipza (oral film).

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required per the approval criteria for commercial and HIM lines of business. Note: aripiprazole ODT does not require prior authorization for Medicaid.

Prior authorization required for commercial and HIM; Medicaid: aripiprazole ODT does not require prior authorization

Step Therapy

Step Therapy Required for Opipza

Step therapy is required for Opipza. Prior authorization for Opipza requires documentation that the member has tried and had inadequate response to, or experienced clinically significant adverse effects from, generic aripiprazole tablet, generic aripiprazole oral solution, and aripiprazole ODT prior to coverage of Opipza.

Step therapy for Opipza requires trial and failure or documented contraindication to: generic aripiprazole tablet; generic aripiprazole oral solution; and aripiprazole ODT
If step therapy is not met, Opipza will not be approved under the step therapy requirement

Quantity Limits by Product

Quantity limits — per product daily tablet/film limits

Per‑product daily limit — Aripiprazole ODT (tablets)ODT: 1–2 tablets per day depending on indication/weight; listed limits include 1 tablet/day for some indications and up to 2 tablets/day for others; maximum dose (all formulations) 30 mg/day for schizophrenia

Per‑product daily limit — Opipza (oral film)Opipza: 2–3 films per day depending on indication/weight (examples: 2 films/day for weight ≥50 kg schizophrenia dosing; up to 3 films/day referenced)

Per‑product daily limit — Mezofy (oral film)Mezofy: 2 films per day referenced as a product-specific per‑day film limit

Unit strengths available (product availability)ODT: 10 mg, 15 mg tablets; Opipza films: 2 mg, 5 mg, 10 mg; Mezofy films: 5 mg, 10 mg, 15 mg

Overall dosing ceilingMaximum dose across aripiprazole ODT and oral film formulations for schizophrenia: 30 mg/day; MDD/autistic disorder max 15 mg/day; Tourette's weight‑based max 10 mg/day (<50 kg) or 20 mg/day (≥50 kg)

Definitions

Definition: ODT

ODT definitionODT = orally disintegrating tablet

ContextUsed in policy to distinguish formulation‑specific dosing and step therapy requirements for aripiprazole

Common strengthsODT available as 10 mg and 15 mg tablets (see product availability)

Definition: MDD

MDD definitionMDD = major depressive disorder

Policy relevanceAripiprazole ODT or Opipza used adjunctively with an antidepressant for MDD; dosing and max dose (15 mg/day) specified

Age requirement

Background

Aripiprazole is an atypical (second‑generation) antipsychotic approved for several psychiatric conditions including schizophrenia, bipolar disorder, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Multiple formulations are available including orally disintegrating tablets (ODT) and newly added oral film products (Opipza and Mezofy), each with indication- and age‑specific approvals and dosing limits; prescribing information and practice guidelines are referenced for clinical details and dosing.